Administration of a probiotic can change drug pharmacokinetics: Effect of E. coli Nissle 1917 on amidarone absorption in rats

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Matuskova, Zuzana ^a   Anzenbacherova, Eva ^a   Vecera, Rostislav ^a   Tlaskalova Hogenova, Helena ^b   Kolar, Milan ^a   Anzenbacher, Pavel ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CYTOCHROME P450 2C; DEETHYLAMIODARONE; PROBIOTIC AGENT; SODIUM CHLORIDE;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; ENZYME ACTIVITY; ESCHERICHIA COLI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; RAT; TREATMENT DURATION;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; ESCHERICHIA COLI; GASTROINTESTINAL TRACT; MALE; PROBIOTICS; RATS; RATS, WISTAR;

EID: 84895508600     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087150     Document Type: Article

References (32)

1. Sommer F, Bäckhed F (2013) The gut microbiota-masters of host development and physiology. Nat Rev Microbiol 11(4): 227-238.
2. Tlaskalová-Hogenová H, Stěpánková R, Kozáková H, Hudcovic T, Vannucci L, et al. (2011) The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germ-free and gnotobiotic animal models of human diseases. Cell Mol Immunol 8(2): 110-120.
3. Meijerink M, Mercenier A, Wells JM (2013) Challenges in translational research on probiotic lactobacilli: from in vitro assays to clinical trials. Benef Microbes 4(1): 83-100.
4. Stojančevic M, Bojič G, Salami HA, Mikov M (2013) The influence of intestinal tract and probiotics on the fate of orally administered drugs. Curr Issues Mol Biol 16(2):55-68.
5. Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, et al. (2013) Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta. Science 341(6143):295-8.
6. Grozdanov L, Zähringer U, Blum-Oehler G, Brade L, Henne A, et al. (2002) A single nucleotide exchange in the wzy gene is responsible for the semirough O6 lipopolysaccharide phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. J Bacteriol 184(21): 5912-5925. (Pubitemid 35168240)
7. Sonnenborn U, Schulze J (2009) The non-pathogenic Escherichia coli Nissle 1917 - features of a versatile probiotic. Microbial Ecology Hlth Dis 21: 122-158.
8. Westendorf AM, Gunzer F, Deppenmeier S, Tapadar D, Hunger JK, et al. (2005) Intestinal immunity of Escherichia coli Nissle 1917: a safe carrier for therapeutic molecules. FEMS Immunol Med Microbiol 43: 373-384. (Pubitemid 40228949)
9. Tannock GW, Tiong IS, Priest P, Munro K, Taylor C, et al. (2011). Testing probiotic strain Escherichia coli Nissle 1917 (Mutaflor) for its ability to reduce carriage of multidrug-resistant E. coli by elderly residents in long283 term care facilities. J Med Microbiol 60: 366-370.
10. Krammer H, Kämper H, von Bünau R, Zieseniß E, Stange C, et al. (2006) Probiotische Arzneimitteltherapie mit E. coli Stamm Nissle 1917 (EcN): Ergebnisse einer prospektiven Datenerhebung mit 3807 Patienten. Z Gastroenterol 44: 651-656. (Pubitemid 44385516)
11. Henker J, Laass M, Blokhin BM, Bolbot YK, Maydannik VG, et al. (2007) The probiotic Escherichia coli strain Nissle 1917 (EcN) stops acute diarrhoea in infants and toddlers. Eur J Pediatrics 166: 311-318. (Pubitemid 46295098)
12. Guarner F, Schlaafsma GJ (1998) Probiotics. Int J Food Microbiol 39: 237-238. (Pubitemid 28132640)
13. Roden DM (1993) Current status of class III antiarrhythmic drug therapy. Am J Cardiol 72: 44B-49B.
14. Van Herendael H, Dorian P (2010) Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. Vasc Hlth Risk Management 6: 465-472.
15. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, et al. (2000) A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: An approach to predict the contribution with relative activity factor. Drug Metab Dispos 28: 1303-1310.
16. Elsherbiny ME, El-Kadi AOS, Brocks DR (2008) The metabolism of amiodarone by various CYP isoenzymes of human and rat, and the inhibitory influence of ketoconazole. J Pharm Pharmaceut Sci 11(1): 147-159.
17. Meng X, Mojaverian P, Doedée M, Lin E, Weinryb I, et al. (2001) Bioavailability of amiodarone tablets administered with and without food in healthy subjects. Am J Cardiol 87: 432-435. (Pubitemid 32150001)
18. Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B (2000) Practical guidelines for clinicians who treat patients with amiodarone. Arch Intern Med 160: 1741-1748. (Pubitemid 30418810)
19. Al-Salami H, Butt G, Fawcett JP, Tucker IG, Golocorbin-Kon S, et al. (2008) Probiotic treatment reduces blood glucose levels and increases systemic absorption of gliclazide in diabetic rats. Eur J Drug Metabol Pharmacokinetics 33(2):101-106.
20. Al-Salami H, Butt G, Tucker I, Skrbic R, Golocorbin-Kon S, et al. (2008) Probiotic pre-treatment reduces gliclazide permeation (ex vivo) in healthy rats but increases it in diabetic rats to the level seen in untreated healthy rats. Arch Drug Info 1:35-41.
21. Lee HJ, Zhang H, Orlovich DA, Fawcett JP (2012) The influence of probiotic treatment on sulfasalazine metabolism in rat. Xenobiotica 42(8): 791-797.
22. Kunes M, Kvetina J, Kholova D, Bures J, Tlaskalova-Hogenova H, et al. (2011) Absorption kinetics of 5-aminosalicylic acid in rat: influence of indomethacin-induced gastrointestinal lesions and Escherichia coli Nissle 1917 medication. Neuro Endocrinol Lett. (Suppl 1): 46-52.
23. Jun AS, Brocks DR (2001). High-performance liquid chromatographic assay of amiodarone in rat plasma. J Pharm Pharmaceut Sci 4(3): 263-268. (Pubitemid 34305603)
24. Sartor RB (2004). Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: Antibiotics, probiotics, and prebiotics. Gastroenterology 126: 1620-1633.
25. Chatelain P, Ferreira J, Laruel R, Ruysschaert JM (1986) Amiodarone-induced modifications of the phospholipid physical state. A fluorescence polarization study. Biochem Pharmacol 35(18): 3007-3013. (Pubitemid 16014692)
26. Boury F, Gautier J-C, Bouligand Y, Proust J-E (2001) Interfacial properties of amiodarone: the stabilizing effect of phosphate anions. Coll Surf B: Biointerfaces 20: 219-227. (Pubitemid 32114114)
27. Sigurdson HH, Kirch J, Lehr C-M (2013) Mucus as a barrier to lipohilic drugs. Intl J Pharmaceutics 453: 56-64.
28. Koenen A, Kroemer HK, Grube M, Meyer zu Schwabedissen HE (2011) Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions. Expert Rev Clin Pharmacol 4(6): 729-742.
29. Le Vee M, Lecureur V, Stieger B, Fardel O (2009) Regulation of drug transporter expression in human hepatocytes exposed to the proinflammatory cytokines tumor necrosis factor-a or interleukin-6. Drug Metab Dispos 37(3): 685-693.
30. Jacobi CA, Malfertheiner P (2011) Escherichia coli Nissle 1917 (Mutaflor): New insights into an old probiotic bacterium. Dig Dis 29: 600-607.
31. Matuskova Z, Tunkova A, Anzenbacherova E, Zidek Z, Tlaskalova-Hogenova H, et al. (2009) Influence of probiotics on rat liver biotransformation enzymes. Neuroendocrinol Lett (Suppl 1): 41-45.
32. Darwich AS, Neuhoff S, Jamei M, Rostami-Hodjegan A (2010) Interplay of metabolism and transport in determing oral drug absorption and gut wall metabolism: a simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Curr Drug Metab 11(9): 716-29.